汗孔角化症胚系与体细胞二次打击变异谱及基因型-表型关联分析
该研究对69例中国汗孔角化症患者进行外周血测序,并对29例患者的37份皮损表皮行全外显子测序以检测体细胞二次打击,同时汇总46项研究共572例患者的胚系基因型与表型数据。研究在MVK、PMVK、MVD和FDPS中检出22个致病变异(含7个新变异),81%(55/68)患者存在体细胞二次打击且具基因亚型特异性,并发现MVD变异与汗孔角化症合并非黑色素瘤皮肤癌及线状汗孔角化症的关联。
要点
- 81%(55/68)患者检出体细胞二次打击,多为拷贝中性杂合性缺失且具基因亚型特异性。
- 合并非黑色素瘤皮肤癌的汗孔角化症患者100%(6/6)携带MVD变异。
- 线状汗孔角化症患者71%(17/24)携带MVD变异,支持基因分型指导临床管理。
核心结论
- 研究扩展了汗孔角化症的遗传变异谱,阐明基因亚型特异的体细胞二次打击机制并建立临床相关基因型-表型关联。
- 这些发现支持以基因检测指导汗孔角化症亚型划分,并为构建分子整合评分系统以完善风险分层管理提供基础。
研究设计与样本
- 对69例汗孔角化症患者的外周血样本进行测序,并对来自29例患者的37份皮损表皮样本行全外显子测序以检测体细胞二次打击改变。
- 回顾PubMed和ClinVar中46项研究报道的572例患者的胚系基因型与表型,分析基因型-表型关联。
主要发现
- 在69例中国汗孔角化症患者中,MVK、PMVK、MVD和FDPS共检出22个致病变异,包括7个新变异,其中4个经二次打击机制验证。
- 结合文献数据总结出10个常见变异,并发现新的基因型-表型关联:合并非黑色素瘤皮肤癌的患者100%(n=6/6)和线状汗孔角化症患者71%(n=17/24)携带MVD变异。
- 在汗孔角化症 ptychotropica(PP)患者中检出MVK、MVD和PMVK变异。
- 81%(n=55/68)患者检出体细胞二次打击改变,主要为拷贝中性杂合性缺失(CN-LOH)且具基因亚型特异性:多数MVK相关汗孔角化症表现为12号染色体全长CN-LOH,多数MVD相关汗孔角化症表现为16q CN-LOH。
临床怎么用
- 可依据基因检测对汗孔角化症进行亚型划分,并识别携带MVD变异等高风险基因型患者以辅助风险分层管理。
局限性
- 作者建议需在更大患者群体中进一步研究,以发现更多遗传病因和潜在治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Porokeratosis is a rare, genetically heterogeneous group of dyskeratotic dermatoses with an incompletely understood pathogenesis. Accumulating evidence shows that pathogenic variants in mevalonate pathway-related genes play a central role in the aetiology of the disease. Previous studies have established partial genotype-phenotype correlations, although the biological mechanisms underlying these associations remain incompletely characterized. OBJECTIVES: To analyse the germline and somatic variant spectrum of porokeratosis, unravel gene subtype-specific 'second-hit' mechanisms, and establish genotype-phenotype correlations via a large cohort, providing evidence to guide clinical practice. METHODS: We sequenced peripheral blood samples from 69 patients with porokeratosis and performed whole-exome sequencing on 37 lesional epidermis samples from 29 patients, to detect somatic second-hit changes. We reviewed the germline genotypes and phenotypes of 572 patients reported in 46 studies retrieved from PubMed and ClinVar, and analysed genotype-phenotype correlations. RESULTS: In 69 Chinese patients with porokeratosis, 22 pathogenic variants were detected in MVK, PMVK, MVD and FDPS, including 7 novel variants, 4 of which were validated via the 'second-hit' mechanism. By integrating this information with literature data, we summarized 10 common variants and identified novel genotypephenotype correlations: 100% (n = 6/6) of patients with porokeratosis plus nonmelanoma skin cancer and 71% (n = 17/24) of those with linear porokeratosis (LP) harboured MVD variants; MVK, MVD and PMVK variants were detected in patients with porokeratosis ptychotropica (PP). Somatic second-hit changes were identified in 81% (n = 55/68) of patients, mostly copy-neutral loss of heterozygosity (CN-LOH) with gene subtype specificity: most MVK-related porokeratosis showed chromosome 12-wide CN-LOH, while most MVD-related porokeratosis had 16q CN-LOH. CONCLUSIONS: Our large cohort study expands the genetic variant spectrum of porokeratosis, clarifies gene subtype-specific somatic 'second-hit' mechanisms and establishes clinically relevant genotype-phenotype correlations. These findings enable porokeratosis subtyping guided by genetic testing and provide a foundation for developing molecularly integrated scoring systems to refine risk-stratified management. Porokeratosis is a rare genetic skin disease. It is related to changes in genes involved in a biological pathway in the body called the ‘mevalonate pathway’. This pathway is essential to how the body uses energy that produces certain molecules, like cholesterol. It is also important for cell growth and development. This study was carried out by researchers from China. We wanted to find the genetic causes of the disease and improve how it is diagnosed. To do this, we took blood samples donated from 69 patients with the disease. Using these blood samples, we analysed their DNA. Twenty-nine patients also donated samples of skin from areas affected by the disease. Finally, we studied the findings of 46 previous studies of the disease that involved 572 other patients. In our analysis, we found seven new gene variants (we used to call these ‘gene mutations’). We also identified 10 common gene variants known to cause disease. Importantly, we linked specific gene changes to particular symptoms. This helps explain why different patients might experience the disease differently. For patients with the disease, our findings may mean a future where personalized treatment based on their unique gene changes may be possible. We recommend further studies with larger groups of patients with the disease. These studies may help discover more genetic causes and potential treatment targets.
引用
- Yang Y, Zhang J, Zhou S, et al. Germline and somatic second-hit changes in porokeratosis: comprehensive variant spectrum and genotype-phenotype correlation analysis. Br J Dermatol. 2026. PMID: 41240373. doi:10.1093/bjd/ljaf461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。